Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.

Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, Cruz FM, Wyrwicz L, Stroyakovskiy D, Pápai Z, Poureau PG, Liposits G, Cremolini C, Bondarenko I, Modest DP, Benhadji KA, Amellal N, Leger C, Vidot L, Tabernero J, SUNLIGHT Investigators

Open source

DOI: 10.1056/nejmoa2214963
Published: 2023 May 4
Container: The New England journal of medicine
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa2214963,
  title = {Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.},
  author = {Prager GW and Taieb J and Fakih M and Ciardiello F and Van Cutsem E and Elez E and Cruz FM and Wyrwicz L and Stroyakovskiy D and Pápai Z and Poureau PG and Liposits G and Cremolini C and Bondarenko I and Modest DP and Benhadji KA and Amellal N and Leger C and Vidot L and Tabernero J and SUNLIGHT Investigators},
  year = {2023},
  journal = {The New England journal of medicine},
  doi = {10.1056/nejmoa2214963},
  url = {https://doi.org/10.1056/nejmoa2214963}
}

RIS

TY  - JOUR
TI  - Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.
AU  - Prager GW
AU  - Taieb J
AU  - Fakih M
AU  - Ciardiello F
AU  - Van Cutsem E
AU  - Elez E
AU  - Cruz FM
AU  - Wyrwicz L
AU  - Stroyakovskiy D
AU  - Pápai Z
AU  - Poureau PG
AU  - Liposits G
AU  - Cremolini C
AU  - Bondarenko I
AU  - Modest DP
AU  - Benhadji KA
AU  - Amellal N
AU  - Leger C
AU  - Vidot L
AU  - Tabernero J
AU  - SUNLIGHT Investigators
PY  - 2023
JO  - The New England journal of medicine
DO  - 10.1056/nejmoa2214963
UR  - https://doi.org/10.1056/nejmoa2214963
ER  -

APA

GW, P., J, T., M, F., F, C., E, V. C., E, E., FM, C., L, W., D, S., Z, P., PG, P., G, L., C, C., I, B., DP, M., KA, B., N, A., C, L., L, V., J, T., & Investigators, S. (2023). Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.. The New England journal of medicine. https://doi.org/10.1056/nejmoa2214963

Source records

pubmed · retrieved 2026-09-27T01:04:33.941Z